Please try another search
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company’s lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Carl L. Gordon | 59 | 2015 | Independent Chairman |
Philip J. Ferneau | 61 | 2015 | Independent Director |
Mary Ann Gray | 71 | 2022 | Independent Director |
F. Stephen Hodi | - | 2019 | Member of Clinical Advisory Board |
Edward Chu | - | 2022 | Member of Clinical Advisory Board |
Richard Goldberg | - | 2022 | Member of Clinical Advisory Board |
James Patrick Boylan | 56 | 2022 | Independent Director |
Richard S. Lindahl | 60 | 2023 | Independent Director |
Thomas J. Schuetz | 63 | 2015 | Co-Founder, President, CEO & Vice Chairman of the Board |
Daniel Douglas Von Hoff | 76 | 2022 | Member of Clinical Advisory Board |
Howard S. Hochster | - | 2022 | Member of Clinical Advisory Board |
Ellen V. Chiniara | 65 | 2022 | Independent Director |
Patricia LoRusso | - | 2022 | Member of Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review